Stock & Company Details
Inhibikase Therapeutics Inc $IKT
Price:
N/A
N/A
140M
$267M
52 Week High:
N/A
10 Day Average Volume:
N/A
-1.66
50 Day Moving Average:
N/A
52 Week Low:
N/A
30 Day Average Volume:
N/A
N/A
N/A
N/A
30 Day Change:
N/A
3 Month Change:
N/A
Health Technology
IKT technical indicators
Latest Inhibikase Therapeutics Inc (IKT) indicator readings as of 2026-10-09.
IKT's 14-day RSI is 37.4, in neutral territory. At $1.97 it is trading 1.1% above its 200-day moving average of $1.95, and below its 50-day average of $2.29. Price sits in the middle of its Bollinger Bands ($1.81 to $2.42). ADX reads 32.6, indicating a trending market.
Overview
Inhibikase Therapeutics Inc is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders. Its multi-therapeutic pipeline focuses on neurodegeneration and its program for IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, intends to treat Parkinson's disease inside and outside the brain. The company is performing its Phase I, randomized single ascending dose and multiple ascending dose, study to determine the safety, tolerability and pharmacokinetics of IkT-148009 in older and healthy subjects. It is also advancing a novel drug delivery platform to treat certain forms of cancer at the same time as it is developing novel drugs for the treatment of neurodegenerative disease.
Finance Bot
Ask your questions
Start by typing a question below.
